National Heart, Lung and Blood Institute (NHLBI)s

National Heart, Lung and Blood Institute (NHLBI)

142 Protocols (82 Active Accrual of new subjects, 60 Follow-up of previously enrolled subjects)


Active Follow-up, Protocols NOT Recruiting New Patients 
* 17-H-0118:
A Phase II Study Of Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

* 17-H-0069:
Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease

* 17-H-0056:
Pathophysiology of Acute Pain in Patients with Sickle Cell Disease

* 16-H-0132:
CADASIL Disease Discovery

* 16-H-0129:
Study to Evaluate the Effect of Nicotinamide Riboside on Immunity

* 16-H-0085:
Pilot Study to Evaluate the Effect of Fasting and Refeeding on T-Cell Fate

* 16-H-0063:
Williams Syndrome Skin and Vascular Elasticity Study (WS-SAVE Study)

* 16-H-0019:
High Image Matrix CT Reconstruction

* 15-H-0172:
A Pilot Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

* 15-H-0155:
Hereditary Parkinson Disease Natural History Protocol

* 15-H-0024:
Genes Involved in Lipid Disorders

* 15-H-0017:
Characterization of Apolipoprotein A-I Pathways in Idiopathic Pulmonary Fibrosis

* 15-H-0016:
A Phase II Study Using ACP-196 in Patients with Relapsed/Refractory and Treatment Naive Deletion 17p CLL/SLL: Pharmacodynamic Assessment of BTK Inhibition and Anti-Tumor Response.

* 14-H-0155:
A Phase 1/2 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the LentiGlobin BB305 Lentiviral Vector in Subjects with Severe Sickle Cell Disease

* 14-H-0077:
Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia in Individuals with Higher Risk of Transplant Failure

* 13-H-0194:
Inflammatory Characterization of Known or Possible Cardiovascular Diseases

* 13-H-0133:
Extended Dosing with Eltrombopag in Refractory Severe Aplastic Anemia

* 13-H-0065:
Human Translational Studies of Inflammation and Cardiometabolic Diseases: The Psoriasis, Atherosclerosis and Cardiometabolic Disease (PACI) Initiative

* 13-H-0060:
Analysis of Samples Collected from a Subject who Received ACP- 501 (Human Recombinant Lecithin:Cholesterol Acyltransferase [rhLCAT])

* 12-H-0110:
An Open-label, Non-Randomized, Single-Arm Pilot Study to Evaluate the Effectiveness of Etidronate Treatment for Arterial Calcifications due to Deficiency in CD73 (ACDC)

* 12-H-0092:
An Intravenous, Open-Label, Single-Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of rhLCAT in Patients with Stable Coronary Artery Disease

* 12-H-0035:
A Phase II study of Ibrutinib for Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Need Therapy and are Older than 65 or have a 17p Deletion

* 11-H-0209:
Male Hormones for Telomere Related Diseases

* 11-H-0134:
A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Moderate Aplastic Anemia Patients

* 11-H-0046:
Cross-Sectional Characterization of Idiopathic Bronchiectasis

* 10-H-0141:
A Phase II Study of Ofatumumab-Based Induction Chemoimmunotherapy Followed by Consolidation Ofatumumab Immunotherapy in Previously Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

* 10-H-0083:
A Phase I Trial of Safety and Immunogenicity of Gardasil Vaccination Post Stem Cell Transplantation in Patients with and without Immunosuppression

* 09-H-0239:
Cellular and Molecular Characterization of the Immune Response in Healthy NIH Employees at Baseline, and After Immunization with the H1N1 or Seasonal Influenza Vaccines

* 09-H-0225:
Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Beta-Thalassemia

* 08-H-0186:
Safety and the Anti- Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK-TRAIL Cytotoxicity with Bortezomib

* 08-H-0046:
Co-Infusion of Umbilical Cord Blood and Haploidentical CD34+ Cells Following Nonmyeloablative Conditioning as Treatment for Severe Aplastic Anemia and MDS Associated with Severe Neutropenia Refractory to Immunosuppressive Therapy

* 07-H-0005:
Pilot Study of Topical Dexamethasone 0.01% Solution for Prevention of Oral Chronic Graft Versus Host Disease

* 06-H-0217:
Genetic Disorders of Mucociliary Clearance

* 06-H-0190:
Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders with Alemtuzumab (Campath)

* 06-H-0072:
Atorvastatin as a Disease Modifying Agent in Stage II and III Pulmonary Sarcoidosis: A Randomized, Double-Blind, Placebo-Controlled Trial

* 03-H-0282:
Characterization of Cardiac Function in Subjects with Hereditary Hemochromatosis Who Are New York Heart Association Functional Class I

* 03-H-0170:
Nonmyeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease (SCD) and B-Thalassemia

* 02-H-0250:
A Phase I/II Study of HLA-matched Mobilized Peripheral Blood Hematopoietic Stem Cell Transplantation for Advanced Mycosis Fungoides/Sezary Syndrome Using Nonmyeloablative Conditioning with Campath-1H

* 01-H-0088:
Determining the Prevalence and Prognosis of Secondary Pulmonary Hypertension in Adult Patients with Sickle Cell Anemia

* 99-H-0050:
Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematologic Malignancies in High Risk Patients and in Patients with Debilitating Hematologic Diseases

* 85-H-0105:
Cardiovascular Evaluation of Homozygous Familial Hypercholesterolemia

* 79-H-0100:
Teaching Protocol for the Evaluation of Plasma Lipoproteins

* 76-H-0051:
Lipoprotein Metabolism in Normal Volunteers and Hyperlipoproteinemic Patients

Previous 100 Protocols

03/29/2024